These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

655 related articles for article (PubMed ID: 37055849)

  • 21. OMIC signatures to understand cancer immunosurveillance and immunoediting: Melanoma and immune cells interplay in immunotherapy.
    León-Letelier RA; Bonifaz LC; Fuentes-Pananá EM
    J Leukoc Biol; 2019 May; 105(5):915-933. PubMed ID: 30698862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Computational Quantification of Cancer Immunoediting.
    Liu K; He S; Sun S; Zhang X; He Y; Quan F; Pang B; Xiao Y
    Cancer Immunol Res; 2023 Sep; 11(9):1159-1167. PubMed ID: 37540180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor-associated macrophages employ immunoediting mechanisms in colorectal tumor progression: Current research in Macrophage repolarization immunotherapy.
    Cheruku S; Rao V; Pandey R; Rao Chamallamudi M; Velayutham R; Kumar N
    Int Immunopharmacol; 2023 Mar; 116():109569. PubMed ID: 36773572
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Of Mice, Dogs, Pigs, and Men: Choosing the Appropriate Model for Immuno-Oncology Research.
    Overgaard NH; Fan TM; Schachtschneider KM; Principe DR; Schook LB; Jungersen G
    ILAR J; 2018 Dec; 59(3):247-262. PubMed ID: 30476148
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The expression pattern of Immune checkpoints after chemo/radiotherapy in the tumor microenvironment.
    Hassanian H; Asadzadeh Z; Baghbanzadeh A; Derakhshani A; Dufour A; Rostami Khosroshahi N; Najafi S; Brunetti O; Silvestris N; Baradaran B
    Front Immunol; 2022; 13():938063. PubMed ID: 35967381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunological-based approaches for cancer therapy.
    Barros L; Pretti MA; Chicaybam L; Abdo L; Boroni M; Bonamino MH
    Clinics (Sao Paulo); 2018 Aug; 73(suppl 1):e429s. PubMed ID: 30133560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms of resistance to T cell-based immunotherapy in head and neck cancer.
    Lee MY; Allen CT
    Head Neck; 2020 Sep; 42(9):2722-2733. PubMed ID: 32275098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Construction and validation of an immunoediting-based optimized neoantigen load (ioTNL) model to predict the response and prognosis of immune checkpoint therapy in various cancers.
    Su X; Jin H; Wang J; Lu H; Gu T; Gao Z; Li M
    Aging (Albany NY); 2022 May; 14(10):4586-4605. PubMed ID: 35613927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune approaches to the treatment of breast cancer, around the corner?
    Criscitiello C; Esposito A; Gelao L; Fumagalli L; Locatelli M; Minchella I; Adamoli L; Goldhirsch A; Curigliano G
    Breast Cancer Res; 2014 Feb; 16(1):204. PubMed ID: 25774617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells.
    Payne KK; Keim RC; Graham L; Idowu MO; Wan W; Wang XY; Toor AA; Bear HD; Manjili MH
    J Leukoc Biol; 2016 Sep; 100(3):625-35. PubMed ID: 26928306
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modeling cancer immunoediting in tumor microenvironment with system characterization through the ising-model Hamiltonian.
    Rojas-Domínguez A; Arroyo-Duarte R; Rincón-Vieyra F; Alvarado-Mentado M
    BMC Bioinformatics; 2022 May; 23(1):200. PubMed ID: 35637445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy.
    Li X; Shao C; Shi Y; Han W
    J Hematol Oncol; 2018 Feb; 11(1):31. PubMed ID: 29482595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SnapShot: Cancer immunoediting.
    Varanasi SK; Kaech SM; Bui JD
    Cell; 2022 Oct; 185(21):4038-4038.e1. PubMed ID: 36240741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.
    Tang T; Huang X; Zhang G; Hong Z; Bai X; Liang T
    Signal Transduct Target Ther; 2021 Feb; 6(1):72. PubMed ID: 33608497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pi (Spleen)-deficiency syndrome in tumor microenvironment is the pivotal pathogenesis of colorectal cancer immune escape.
    Sun XG; Lin XC; Diao JX; Yu ZL; Li K
    Chin J Integr Med; 2016 Oct; 22(10):789-94. PubMed ID: 26556710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy.
    Xie G; Cheng T; Lin J; Zhang L; Zheng J; Liu Y; Xie G; Wang B; Yuan Y
    J Immunother Cancer; 2018 Sep; 6(1):88. PubMed ID: 30208943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting innate sensing in the tumor microenvironment to improve immunotherapy.
    Liu Z; Han C; Fu YX
    Cell Mol Immunol; 2020 Jan; 17(1):13-26. PubMed ID: 31844141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Translation of cancer immunotherapy from the bench to the bedside.
    Guo Q; Huang F; Goncalves C; Del Rincón SV; Miller WH
    Adv Cancer Res; 2019; 143():1-62. PubMed ID: 31202357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanotechnology for Boosting Cancer Immunotherapy and Remodeling Tumor Microenvironment: The Horizons in Cancer Treatment.
    Gao S; Yang X; Xu J; Qiu N; Zhai G
    ACS Nano; 2021 Aug; 15(8):12567-12603. PubMed ID: 34339170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy.
    Zhao B; Li H; Xia Y; Wang Y; Wang Y; Shi Y; Xing H; Qu T; Wang Y; Ma W
    J Hematol Oncol; 2022 Oct; 15(1):153. PubMed ID: 36284349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.